Logo for Karyopharm Main Menu Financial Information This section of the Karyopharm Therapeutics InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing. Please note: All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes. Karyopharm Therapeutics assumes no responsibility for the accuracy of this data and provides it for informational purposes only. NASDAQKPTI Loading... 1dy 1mo 6mo 1yr 5yr Beta 0.07 Shares Outstanding 75.5M Average Volume (10 days) 1.6M Qtrly Dividend (Ann. Yield) -- (--) PER SHARE DATA Earnings (TTM) ($2.75) Sales (TTM) $1.57 Book Value (MRQ) ($1.67) Cash Flow (TTM) ($2.18) Cash (MRQ) $2.71 ANALYST VIEWS Current Mean Recommendation Hold Strong Buy 3 Buy 0 Hold 4 Underperform 0 Sell 1 RECENT INSIDER TRANSACTIONS Jatin Shah EVP, Chief Medical Officer (665) Dispose Jul 12, 2021 Sohanya Roshan Cheng SVP Sales & Commercial Ops 7,500 Acquire Jun 30, 2021 Stephen Mitchener SVP, Chief Business Officer (528) Sell Jun 2, 2021 Jatin Shah EVP, Chief Medical Officer 23,250 Buy May 7, 2021 Garen G. Bohlin Director 4,000 Buy May 6, 2021 RECENT SEC FILINGS 10-Q Quarterly Financials Nov 3, 2021 8-K Company Events Nov 3, 2021 SC 13G/A Amended >= 5% Acquisition Oct 12, 2021 S-8 S-8 Aug 5, 2021 S-3ASR S-3ASR Aug 5, 2021 Currency in USD. Quote data delayed by at least 15 minutes. Earnings and Analyst data provided by Zacks. Insiders data provided by Morningstar. © Karyopharm, 2020. All Rights Reserved. Terms of Use Privacy Policy Site Map